55658-71-4Relevant academic research and scientific papers
(+)-trans-Cannabidiol-2-hydroxy pentyl is a dual CB1R antagonist/CB2R agonist that prevents diabetic nephropathy in mice
González-Mariscal, Isabel,Carmona-Hidalgo, Beatriz,Winkler, Matthias,Unciti-Broceta, Juan D.,Escamilla, Alejandro,Gómez-Ca?as, María,Fernández-Ruiz, Javier,Fiebich, Bernd L.,Romero-Zerbo, Silvana-Yanina,Bermúdez-Silva, Francisco J.,Collado, Juan A.,Mu?oz, Eduardo
, (2021/06/02)
Natural cannabidiol ((-)-CBD) and its derivatives have increased interest for medicinal applications due to their broad biological activity spectrum, including targeting of the cannabinoid receptors type 1 (CB1R) and type 2 (CB2R). Herein, we synthesized the (+)-enantiomer of CBD and its derivative (+)-CBD hydroxypentylester ((+)-CBD-HPE) that showed enhanced CB1R and CB2R binding and functional activities compared to their respective (-) enantiomers. (+)-CBD-HPE Ki values for CB1R and CB2R were 3.1 ± 1.1 and 0.8 ± 0.1 nM respectively acting as CB1R antagonist and CB2R agonist. We further tested the capacity of (+)-CBD-HPE to prevent hyperglycemia and its complications in a mouse model. (+)-CBD-HPE significantly reduced streptozotocin (STZ)-induced hyperglycemia and glucose intolerance by preserving pancreatic beta cell mass. (+)-CBD-HPE significantly reduced activation of NF-κB by phosphorylation by 15% compared to STZ-vehicle mice, and CD3+ T cell infiltration into the islets was avoided. Consequently, (+)-CBD-HPE prevented STZ-induced apoptosis in islets. STZ induced inflammation and kidney damage, visualized by a significant increase in plasma proinflammatory cytokines, creatinine, and BUN. Treatment with (+)-CBD-HPE significantly reduced 2.5-fold plasma IFN-γ and increased 3-fold IL-5 levels compared to STZ-treated mice, without altering IL-18. (+)-CBD-HPE also significantly reduced creatinine and BUN levels to those comparable to healthy controls. At the macroscopy level, (+)-CBD-HPE prevented STZ-induced lesions in the kidney and voided renal fibrosis and CD3+ T cell infiltration. Thus, (+)-enantiomers of CBD, particularly (+)-CBD-HPE, have a promising potential due to their pharmacological profile and synthesis, potentially to be used for metabolic and immune-related disorders.
Method for preparing cannabinoids
-
Page/Page column 10, (2021/04/21)
Provided is a method for preparing synthetic cannabidiol, including hydrolysis-decarboxylation of a compound represented by formula (II) in a solvent-free state under atmospheric pressure. The method further includes preparation of the compound represented by formula (II). The method provides a safe, economical, environmentally friendly and scalable method for synthetic preparation of cannabidiol.
CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF
-
, (2021/02/26)
The present disclosure provides pharmaceutical compositions including a cannabinoid acid ester compound alone or in combination with one or more additional cannabinoid compounds. In some embodiments, the cannabinoid acid ester compound is a tetrahydrocann
CANNABIDIOLIC ACID (CBDA) DERIVATIVES AND USES THEREOF
-
, (2021/12/31)
The present invention provides novel compounds comprising cannabidiolic acid (CBDA) derivatives, including acids and esters, and uses thereof in the treatment of various diseases, disorders, conditions and symptoms.
CANNABIDIOLIC ACID (CBDA) DERIVATIVES AND USES THEREOF
-
, (2021/12/31)
The present invention provides novel compounds comprising cannabidiolic acid (CBDA) derivatives, including acids and esters, and uses thereof in the treatment of various diseases, disorders, conditions and symptoms.
CANNABIDIOLIC ACID ESTERS FOR TREATING MUSCULAR DYSTROPHY
-
Page/Page column 41, (2021/07/10)
The present invention provides compositions and methods for treating muscular dystrophy. In particular, the present invention provides pharmaceutical compositions and formulations comprising a cannabidiolic acid (CBDA) ester alone or in combination with o
CANNABIDIOLIC ACID (CBDA) DERIVATIVES AND USES THEREOF
-
Page/Page column 46, (2021/12/31)
The present invention provides novel compounds comprising cannabidiolic acid (CBDA) derivatives, including acids and esters, and uses thereof in the treatment of various diseases, disorders, conditions and symptoms.
METHODS OF MANUFACTURING CANNABIDIOL OR CANNABIDIVARIN AND INTERMEDIATES OF MANUFACTURING CANNABIDIOL OR CANNABIDIVARIN
-
Page/Page column 14, (2020/11/30)
Methods of manufacturing cannabidiol (CBD) and cannabidivarin (CBDV); intermediates of the methods of manufacturing CBD and CBDV; and crystallized CBD and CBDV obtained via described methods.
CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF
-
, (2020/09/30)
The present disclosure provides pharmaceutical compositions including a cannabinoid acid ester compound alone or in combination with one or more additional cannabinoid compounds. In some embodiments, the cannabinoid acid ester compound is a cannabidiolic
CANNABIDIOLIC ACID ESTERS FOR COSMETIC OR EDIBLE COMPOSITIONS
-
Page/Page column 39, (2020/07/15)
The present invention provides cosmetic or edible compositions comprising a cannabinoid component, wherein the cannabinoid component comprises a cannabidiolic acid (CBDA) ester alone or in combination with one or more cannabinoid compound(s), and a physio
